A Personalized Approach to Managing Inflammatory Bowel Disease

Overview

Journal Gastroenterol Hepatol (N Y)

Specialty Gastroenterology

Date 2016 Aug 9

PMID 27499713

Citations 12

Authors

Michael J Kingsley

Maria T Abreu

Affiliations

Soon will be listed here.

Abstract

The management of inflammatory bowel disease (IBD) requires a personalized approach to treat what is a heterogeneous group of patients with inherently variable disease courses. In its current state, personalized care of the IBD patient involves identifying patients at high risk for rapid progression to complications, selecting the most appropriate therapy for a given patient, using therapeutic drug monitoring, and achieving the individualized goal that is most appropriate for that patient. The growing body of research in this area allows clinicians to better predict outcomes for individual patients. Some paradigms, especially within the realm of therapeutic drug monitoring, have begun to change as therapy is targeted to individual patient results and goals. Future personalized medical decisions may allow specific therapeutic plans to draw on serologic, genetic, and microbial data for Crohn's disease and ulcerative colitis patients.

Citing Articles

Placebo-Controlled Trials in the Management of Crohn's Disease: An Umbrella Review of Meta-Analyses.

Silva R, Azevedo J, Machado J, Rodrigues J Med Sci (Basel). 2025; 13(1).

PMID: 39982236 PMC: 11843887. DOI: 10.3390/medsci13010012.

Enhanced Risk of Gastroesophageal Reflux Disease and Esophageal Complications in the Ulcerative Colitis Population.

Wang X, Almetwali O, Wang J, Wright Z, Patton-Tackett E, Roy S J Clin Med. 2024; 13(16).

PMID: 39200925 PMC: 11355171. DOI: 10.3390/jcm13164783.

Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects.

Suri C, Pande B, Sahu T, Suhasini Sahithi L, Verma H J Clin Med. 2024; 13(13).

PMID: 38999541 PMC: 11242723. DOI: 10.3390/jcm13133977.

Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond.

Sahle Z, Engidaye G, Gebreyes D, Adenew B, Abebe T SAGE Open Med. 2024; 12:20503121241257486.

PMID: 38826830 PMC: 11143861. DOI: 10.1177/20503121241257486.

Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing.

Koster F, Kok M, van der Kooij J, Waverijn G, Weel-Koenders A, Barreto D Pharmacoecon Open. 2023; 7(4):593-603.

PMID: 37129793 PMC: 10152001. DOI: 10.1007/s41669-023-00413-2.

References

Gazouli M, Anagnostopoulos A, Papadopoulou A, Vaiopoulou A, Papamichael K, Mantzaris G . Serum protein profile of Crohn's disease treated with infliximab. J Crohns Colitis. 2013; 7(10):e461-70. DOI: 10.1016/j.crohns.2013.02.021. View

Winter J, Gaffney D, Shapiro D, Spooner R, Marinaki A, Sanderson J . Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25(9):1069-77. DOI: 10.1111/j.1365-2036.2007.03301.x. View

Frank D, Robertson C, Hamm C, Kpadeh Z, Zhang T, Chen H . Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2010; 17(1):179-84. PMC: 3834564. DOI: 10.1002/ibd.21339. View

Dubinsky M, Lamothe S, Yang H, Targan S, Sinnett D, Theoret Y . Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000; 118(4):705-13. DOI: 10.1016/s0016-5085(00)70140-5. View

Wang W, Chen L, Zhou R, Wang X, Song L, Huang S . Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014; 52(2):398-406. PMC: 3911339. DOI: 10.1128/JCM.01500-13. View

Rossen N, Fuentes S, van der Spek M, Tijssen J, Hartman J, Duflou A . Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015; 149(1):110-118.e4. DOI: 10.1053/j.gastro.2015.03.045. View

Sparrow M, Hande S, Friedman S, Lim W, Reddy S, Cao D . Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005; 22(5):441-6. DOI: 10.1111/j.1365-2036.2005.02583.x. View

Sherlock M, Walters T, Tabbers M, Frost K, Zachos M, Muise A . Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr. 2013; 56(5):512-8. DOI: 10.1097/MPG.0b013e31828390ba. View

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

10.

Osterman M, Kundu R, Lichtenstein G, Lewis J . Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006; 130(4):1047-53. DOI: 10.1053/j.gastro.2006.01.046. View

11.

Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M . Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol. 2013; 49(1):100-9. DOI: 10.1007/s00535-013-0803-4. View

12.

Sokol H, Seksik P, Furet J, Firmesse O, Nion-Larmurier I, Beaugerie L . Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009; 15(8):1183-9. DOI: 10.1002/ibd.20903. View

13.

Michail S, Durbin M, Turner D, Griffiths A, Mack D, Hyams J . Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis. 2011; 18(10):1799-808. PMC: 3319508. DOI: 10.1002/ibd.22860. View

14.

Seow C, Newman A, Irwin S, Steinhart A, Silverberg M, Greenberg G . Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2009; 59(1):49-54. DOI: 10.1136/gut.2009.183095. View

15.

Lichtenstein G, Targan S, Dubinsky M, Rotter J, Barken D, Princen F . Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis. 2011; 17(12):2488-96. PMC: 4203682. DOI: 10.1002/ibd.21661. View

16.

Bendtzen K, Ainsworth M, Steenholdt C, Thomsen O, Brynskov J . Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009; 44(7):774-81. DOI: 10.1080/00365520802699278. View

17.

Singh N, Rosenthal C, Melmed G, Mirocha J, Farrior S, Callejas S . Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20(10):1708-13. DOI: 10.1097/MIB.0000000000000137. View

18.

Ananthakrishnan A, Huang H, Nguyen D, Sauk J, Yajnik V, Xavier R . Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol. 2014; 109(3):395-400. PMC: 4225079. DOI: 10.1038/ajg.2013.464. View

19.

Yarur A, Abreu M, Deshpande A, Kerman D, Sussman D . Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol. 2014; 20(13):3475-84. PMC: 3974514. DOI: 10.3748/wjg.v20.i13.3475. View

20.

Brant S, Picco M, Achkar J, Bayless T, Kane S, Brzezinski A . Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003; 9(5):281-9. DOI: 10.1097/00054725-200309000-00001. View